Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1
OBR Daily - Our Oncology Focused E-News Service

Register for OBR daily



Warning: Missing argument 1 for showSidebarBanner(), called in /home2/don/public_html/sidebar_obrgreen.php on line 38 and defined in /home2/don/public_html/include/banners.php on line 243
FM_ROS_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

FPRX $20.70 4.9500 +31.43%
ARIA $7.15 0.6300 +9.66%
CNDO $2.04 0.1600 +8.51%
TSRO $33.32 2.5900 +8.43%
CYTK $4.42 0.3100 +7.54%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GALE $1.89 -0.1800 -8.70%
BIND $7.02 -0.5300 -7.02%
CERU $4.91 -0.3000 -5.76%
FATE $3.99 -0.2400 -5.67%
MRTX $15.51 -0.5000 -3.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Dr Reddy's Gets FDA Approval For Roche Drug Generic; Shares at Record High

(Reuters) Nov 7, 2014 - Indian drugmaker Dr Reddy's Laboratories Ltd said on Friday it has received final approval from the U.S. Food and Drug Administration (FDA) to make a cheaper version of Roche Holding AG's antiviral Valcyte, sending its stock to a record high.
read article 



Boehner Says Rolling Back Obamacare Is GOP Priority

(NPR/The Two-Way blog) Nov 6, 2014 - House Speaker John Boehner said approval of the controversial Keystone XL oil pipeline and the repeal of key parts of Obamacare are among Republicans' top priorities now that the GOP has won control of both houses of Congress.
read article 



NIH Launches Online Database For International Clinical Research Regulations

(ASCO in Action) Nov 6, 2014 - The National Institute of Health (NIH) has launched ClinRegs, a new website that provides clinical research regulatory information for 12 of the top countries that conduct clinical research.
read article 



Don't Reform the Malpractice System to Reduce Healthcare Costs -- Eliminate It

(Forbes) Nov 5, 2014 - There is nothing more time consuming and expensive for a patient than undergoing extra tests or procedures during a trip to the emergency room, doctor’s office or urgent care center.
read article 



Voters Provide Mixed Messages on Health Ballot Measures

(Kaiser Health News) Nov 5, 2014 - The Affordable Care Act wasn’t directly on the ballot in any state, but voters did decide a host of health-related issues in Tuesday’s elections.
read article 



Dr. Steven Finkelstein Named Chief Science Officer at 21st Century Oncology

(21st Century Oncology) Nov 4, 2014 - 21st Century Oncology, the nation’s leading provider of cancer care services, has recently appointed Scottsdale Board Certified Radiation Oncologist, Steven Finkelstein, M.D., as the company’s national Chief Science Officer.
read corporate press release 



Bristol-Myers Squibb Receives the LEAD Award From The US Oncology Network

(The US Oncology Network) Nov 7, 2014 - Today, The US Oncology Network, one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care, presented Bristol-Myers Squibb (BMS) with the inaugural LEAD Award during The Network’s Joint Fall Pharmacy & Therapeutics (P&T) and Annual Radiation & Imaging Meeting in Dallas.
read corporate press release 



INC Research Announces Pricing of Initial Public Offering

(Yahoo! Finance) Nov 6, 2014 - INC Research Holdings, Inc., a leading, global Phase I to IV contract research organization, today announced the pricing of its initial public offering of 8,108,108 shares of its Class A common stock at a price to the public of $18.50 per share.
read article 



The Decline of a Top Cancer Agency

(Medscape Medical News) Nov 6, 2014 - The British Columbia (BC) Cancer Agency has had an international reputation for excellence in care and research.
read article (free registration required) 



Brain Tumor Community Pushes For Inclusion of Patient-Focused Endpoints in Future Clinical Trials

(National Brian Tumor Society) Nov 6, 2014 - A recent workshop brought together leaders and stakeholders from the neuro-oncology, neurology, and clinical outcomes assessment fields to address the critical issue of incorporating patient-focused endpoints into future brain cancer clinical trials.
read press release 



Racial Gap Growing in Breast Cancer Deaths

(Milwaukee Journal-Sentinel) Nov 6, 2014 - African-American women are much more likely to die of breast cancer than white women.
read article 



Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 For Brain Cancer

(Merrimack) Nov 6, 2014 - Merrimack Pharmaceuticals, Inc. today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398 (nanoliposomal irinotecan injection) in a highly concentrated formulation in patients with recurrent high grade glioma, a type of aggressive brain tumor with poor prognosis.
read corporate press release 



Op-Ed: Why Women Need More Science With Their Breast Cancer Survival Stories

(Los Angeles Times) Nov 5, 2014 - October was National Breast Cancer Awareness Month. Football players took to the field in splashes of pink, and women's magazines featured celebrity survivors such as Suzanne Somers and Sheryl Crow, smiling alongside headlines attributing breast cancer survival to an upbeat attitude, personal fortitude and a conscientious shift toward a more healthful lifestyle.
read article (free registration required) 



Newly Identified Network Triggers Degradation of Important Tumor Suppressor Protein in Triple Negative Breast Cancer

(Baylor College of Medicine) Nov 7, 2014 - Researchers from Baylor College of Medicine have identified a network of proteins that triggers triple negative breast cancer – one of the most aggressive and difficult-to-treat forms of the disease.
read press release 



UCLA Study Finds Tai Chi Reduces Inflammation in Breast Cancer Survivors

(UCLA Newsroom) Nov 6, 2014 - UCLA researchers have discovered that the Chinese practice of tai chi can reduce inflammation in people who have had breast cancer, thereby reducing a risk factor for the recurrence of the cancer.
read article 



Convocating Student Explores Impact of Patient's Death on Nurses

(University of Calgary/UToday [Canada]) Nov 7, 2014 - When a child dies from cancer, it is almost unbearably tragic for family and friends. And, as a recent research study indicates, it may also adversely affect the career of the registered nurse who cared for that child.
read article 



Migration Negation

(Harvard Medical School) Nov 6, 2014 - Most cancer deaths occur because of metastasis, yet progress in preventing and treating migratory cancer cells has been slow.
read article 



Biothera's Imprime PGG Inhibits Cancer Defense Mechanism

(Yahoo! Finance) Nov 6, 2014 - New data demonstrates that Biothera’s immunotherapy drug candidate inhibits a cancer defense mechanism that recruits and polarizes certain immune cells for its own protection and growth.
read article 



Myriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans

(Myriad) Nov 7, 2014 - Myriad Genetics, Inc. today presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill.
read corporate press release 



Penn Medicine Study: Olaparib Shows Success in Tumor Response Rate For Patients With BRCA-Related Cancers

(Penn Medicine) Nov 6, 2014 - Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.
read press release 



Oncology Stakeholders Agree: In a Shifting Healthcare Environment, Communicating Quality Is Critical

(ACCC) Nov 6, 2014 - In a healthcare system that is increasingly shifting from volume to value, how do payers and patients distinguish quality cancer care?
read press release 



International Myeloma Foundation Expresses Disappointment at Oncologic Drugs Advisory Committee (ODAC) Recommendation Against New Myeloma Treatment Panobinostat

(IMF) Nov 6, 2014 - On November 6, 2014 an FDA advisory panel, the Oncologic Drugs Advisory Committee (ODAC), held a hearing on panobinostat, a drug in development to treat relapsed myeloma.
read press release 



France Asks Roche For Data on Use of Cancer Drug Avastin in Eye

(Reuters) Nov 6, 2014 - French medicine agency ANSM has written to Roche asking the Swiss drugmaker for information on off-label uses of its cancer drug Avastin, which ANSM wants to let doctors prescribe as a cheap alternative eye treatment.
read article 



New Patient Receiving BlueBird Gene Therapy Responding More Slowly

(TheStreet) Nov 6, 2014 - The new clinical data on Bluebird's gene therapy is contained in a just-released abstract ahead of next month's American Society of Hematology (ASH) annual meeting.
read article 



J&J Wins U.S. Approval For Hepatitis C Combo With Gilead

(Bloomberg) Nov 6, 2014 - Johnson & Johnson won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc.’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.
read article